MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells

por Nishidate, Masanobu, Yamamoto, Kaname, Masuda, Chinami, Aikawa, Hiroaki, Hayashi, Mitsuhiro, Kawanishi, Takehiko, Hamada, Akinobu
Publicado 2017

PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8(+) T cells in hematogenous metastasis model with lymphocyte infusion

por Masuda, Chinami, Morinaga, Mamiko, Wakita, Daiko, Yorozu, Keigo, Kurasawa, Mitsue, Sugimoto, Masamichi, Kondoh, Osamu
Publicado 2021

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model

por Masuda, Chinami, Yanagisawa, Mieko, Yorozu, Keigo, Kurasawa, Mitsue, Furugaki, Koh, Ishikura, Nobuyuki, Iwai, Toshiki, Sugimoto, Masamichi, Yamamoto, Kaname
Publicado 2017

Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model

por Masuda, Chinami, Sugimoto, Masamichi, Wakita, Daiko, Monnai, Makoto, Ishimaru, Chisako, Nakamura, Ryo, Kinoshita, Mari, Yorozu, Keigo, Kurasawa, Mitsue, Kondoh, Osamu, Yamamoto, Kaname
Publicado 2019